Emagliflozin S 10/100

Emagliflozin S 10/100 is a dual-action oral antidiabetic medicine containing Empagliflozin (10 mg), an SGLT2 inhibitor, and Sitagliptin (100 mg), a DPP-4 inhibitor. This combination is designed to provide effective glycemic control in patients with Type 2 Diabetes Mellitus (T2DM) by working through complementary mechanisms.

• Empagliflozin 10 mg: Helps kidneys remove excess glucose via urine, thereby lowering blood sugar levels and supporting weight reduction.

• Sitagliptin 100 mg: Enhances the body’s natural ability to regulate blood sugar by increasing insulin release and decreasing glucagon secretion after meals.

This dual therapy offers better control of HbA1c, reduces the risk of diabetes-related complications, and may provide additional cardiovascular and renal protection.

Key Benefits:

• Effective dual therapy for Type 2 Diabetes management

• Helps lower fasting and postprandial blood sugar levels

• Reduces HbA1c levels significantly

• Aids in weight management with low risk of hypoglycemia

• Supports heart and kidney health in diabetic patients

• Convenient once-daily dosing